Transforming Biopharma: The Impact of Digital PCR on Quantification in Biopharma Research And Manufacturing
In the rapidly evolving landscape of biopharmaceutical research, digital PCR (dPCR) has fundamentally transformed the way we approach quantification and analysis. This webinar, featuring Dr. David Dobnik, explores the journey of dPCR from a novel technique to an essential tool in the biopharma industry.
Dr. Dobnik will delve into its broad-ranging applications, the advantages it offers over traditional PCR methods, and how it has become a critical component in the development and refinement of gene therapies.
Why you should join:
- Learn directly from a leading expert and visionary in biopharmaceutical research and gene therapy
- Discover why digital PCR has become an essential tool in gene therapy research and manufacturing
- Understand the multiplexing capabilities of the latest digital PCR instruments
- Take home process improvements to enhance your lab workflow
Can’t make it? Register to receive a recording.
About the speaker
David Dobnik, PhD in Biotechnology, has been developing new nucleic acid detection/quantification approaches since 2007. He's been working with digital PCR since 2012. From 2016, he has been closely working with companies in the field of gene therapy (such as AveXis (now Novartis Gene Therapies)) to develop and apply methods for precise quantification of viral vectors (e.g. dPCR),observation of viral particles (electron microscopy), and for identification and quantification of impurities (e.g. nucleic acids by high-throughput sequencing (HTS/NGS).
David has been leading the development and tech-transfer projects for pharmaceutical companies focused on the field of gene therapy,helping their process development efforts with characterizations of viral vectors. Lately, most of his work has been focused on developing new approaches for genome integrity evaluation.
Dr. David Dobnik
National Institute of Biology
Register for our webinar today
